Stuart Therapeutics, established in 2017 is developing PolyCol, a unique therapeutic platform that is a direct tissue reparative for collagen membranes and structures in the eye. This unique method of action results in accelerated healing and recovery in various ophthalmic disease states, and offers a new way to address indications such as dry eye disease, dry age related macular degeneration and glaucoma.
PolyCol is based on patented research from a major U.S. university, combined with additional intellectual property acquired by Stuart Therapeutics.
Stuart’s first drug candidate based on the PolyCol platform, ST-100, is an extremely fast acting therapeutic that directly addresses the corneal tissue damage associated with dry eye disease.
Stuart Therapeutics was founded to bring a fresh point of view to the development of therapies for difficult to treat ophthalmic diseases. Our team brings a wide variety of proven clinical, pharmaceutical R&D, operational and partnering skills to support our venture. Our core inventor group identified the promise of PolyCol and has established broad patent coverage to provide the company with an array of options for partnering and internal development. The areas of medicine on which we are focused have affected all of the members of our team, either directly or indirectly. We have a passion for what we do, and a motivation to improve results for patients suffering from these conditions.
Stuart Therapeutic has augmented its team with widely recognized advisors each of whom are prominent in their fields of expertise. They complement our management team, and we are both proud and privileged that they are working with us in this important effort.
Stuart Therapeutics… Delivers.
Stuart Therapeutics’ mission is the development of new and meaningful therapies
that improve the lives of people that suffer from difficult to treat diseases.
It is wonderful what great strides can be made when there is a resolute purpose behind them. – Sir Winston Churchill